An Ultrasensitive Assay for Measurement of Levels of Cathepsin B in the Blood
|
By LabMedica International staff writers Posted on 21 Apr 2021 |

Image: Representation of the molecular structure of the cathepsin B (catB) protein (Photo courtesy of Wikimedia Commons)
A novel digital enzyme-linked immunosorbent assay (ELISA) has been developed for the differential detection of cathepsin B from samples of serum or plasma.
Cathepsin B (catB) is a lysosomal cysteine protease expressed in various cells and organs, where it plays a role in protein degradation and turnover. Under pathological conditions, catB expression becomes upregulated in a variety of diseases including metastatic cancers, infections, traumatic brain injury, and neurological diseases. This upregulation is often associated with increased extracellular secretion via active or passive mechanisms. As such, the catB protein content is elevated above basal levels where it may have utility as a biofluid-based marker of diseases, injury, or trauma.
While biofluid samples such as plasma and serum contain catB, it is often difficult to obtain accurate measurements of the protein due to background interference and high variance, which limit the usefulness of catB as a peripheral biomarker. Thus, techniques for ultrasensitive protein detection that require low volumes of sample are necessary.
In this regard, investigators at Walter Reed Army Institute for Research (Silver Spring, MD, USA) developed a digital ELISA for differential detection of catB within less than five microliters of serum and plasma using the single molecule array (SiMoA) platform, which offers 1000-times more sensitivity and vastly reduced variance compared to colorimetric tests.
Results revealed that in buffer solution, the limit of detection (LoD) was between 1.56 and 8.47 picograms per milliliter depending on whether a two-step or three-step assay was used. After correcting for endogenous levels, the estimated LoD was approximately 4.7 picograms per milliliter in serum or plasma with the two-step assay. The lower limit of quantitation was about 2.3 picograms per milliliter in buffer and about 9.4 picograms per milliliter in serum or plasma, indicting the ability to measure small changes above endogenous levels within blood samples.
"Although cathepsin can be abundant in some tissues, accurate measurement in blood has been a challenge, especially if changes are expected to be small or sample is limited," said first author Dr. Bharani Thangavelu, a researcher in the brain trauma neuroprotection branch at the Walter Reed Army Institute for Research. "Our strategy uses an ultrasensitive technique to improve cathepsin B detection from small volumes of blood with little to no noise or impact from interfering substances."
The ultrasensitive ELISA for cathepsin B was described in the March 31, 2021, online edition of the journal ACS Omega.
Related Links:
Walter Reed Army Institute for Research
Cathepsin B (catB) is a lysosomal cysteine protease expressed in various cells and organs, where it plays a role in protein degradation and turnover. Under pathological conditions, catB expression becomes upregulated in a variety of diseases including metastatic cancers, infections, traumatic brain injury, and neurological diseases. This upregulation is often associated with increased extracellular secretion via active or passive mechanisms. As such, the catB protein content is elevated above basal levels where it may have utility as a biofluid-based marker of diseases, injury, or trauma.
While biofluid samples such as plasma and serum contain catB, it is often difficult to obtain accurate measurements of the protein due to background interference and high variance, which limit the usefulness of catB as a peripheral biomarker. Thus, techniques for ultrasensitive protein detection that require low volumes of sample are necessary.
In this regard, investigators at Walter Reed Army Institute for Research (Silver Spring, MD, USA) developed a digital ELISA for differential detection of catB within less than five microliters of serum and plasma using the single molecule array (SiMoA) platform, which offers 1000-times more sensitivity and vastly reduced variance compared to colorimetric tests.
Results revealed that in buffer solution, the limit of detection (LoD) was between 1.56 and 8.47 picograms per milliliter depending on whether a two-step or three-step assay was used. After correcting for endogenous levels, the estimated LoD was approximately 4.7 picograms per milliliter in serum or plasma with the two-step assay. The lower limit of quantitation was about 2.3 picograms per milliliter in buffer and about 9.4 picograms per milliliter in serum or plasma, indicting the ability to measure small changes above endogenous levels within blood samples.
"Although cathepsin can be abundant in some tissues, accurate measurement in blood has been a challenge, especially if changes are expected to be small or sample is limited," said first author Dr. Bharani Thangavelu, a researcher in the brain trauma neuroprotection branch at the Walter Reed Army Institute for Research. "Our strategy uses an ultrasensitive technique to improve cathepsin B detection from small volumes of blood with little to no noise or impact from interfering substances."
The ultrasensitive ELISA for cathepsin B was described in the March 31, 2021, online edition of the journal ACS Omega.
Related Links:
Walter Reed Army Institute for Research
Latest Molecular Diagnostics News
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
- Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








